introduction: Vitamin D deficiency is an important public health problem worldwide. Vitamin D deficiency confers a significant risk for both skeletal and non-skeletal disorders and a number of lifelong negative health outcomes. The objectives of this evidence-based guidelines document are to provide health care professionals in Poland, an updated recommendation for the prevention, diagnosis and treatment of vitamin D deficiency.
vitamin D deficiency of varying severity has been found in 90% of adults, children and adolescents (4) (5) (6) (7) . Vitamin D deficiency may be associated with its well-known calcemic effect as well as a broad spectrum of pleiotropic effects, the latter having been studied intensely in recent decades. Hence, the problem of vitamin D deficiency and its adequate supply represent an important issue in public health and clinical practice. Guidelines for vitamin D supplementation undergo modifications every few years, in view of new findings resulting in changing the paradigms. The global consensus on prevention and management of nutritional rickets was published in 2016 (8) , which due to discrepancies with recommendations for the Central Europe (9) and previous Polish guidelines (10) , evoked polemical discussion and dilemmas among doctors of many specialties, particularly among pediatric endocrine and diabetes specialists. Therefore, in 2017 The Board of the Polish Society of Pediatric Endocrinology and Diabetes came up with an initiative on verifying and updating ruling recommendations on prevention and management of vitamin D deficiency, both in the general population and in the risk groups. In cooperation with the European Vitamin D Association (EVIDAS) and other scientific societies and National Consultants, the Expert Panel was constituted to elaborate current guidelines for supplementation and treatment with vitamin D, based on recent literature reviews, personal clinical experience and critical discussion.
MeTHODS
The Expert Panel with the participation of National Consultants and Representatives of Scientific Societies, basing on the literature review and evaluation of strength and quality of evidence, developed current recommendations for prevention and treatment of vitamin D deficiency in the general population and in the risk groups.
For each point listed below, recommendations and a level of evidence are described, with following modification in the grading evidence: 1 = strong recommendation (application in the general population and in all patients in most circumstances, benefits clearly overweigh the risk) and 2-weak recommendation (consensus opinion of working group or to be considered; the best action may depend on circumstances, benefits and risk closely balanced or uncertain). Quality of evidence was assigned as follows: ⊕⊕⊕ high quality [prospective cohort or randomized controlled trials (RCT) studies, at low risk of bias]; ⊕⊕ moderate quality (observational or clinical trials with methodological flaws, inconsistent or indirect evidence) and ⊕ low quality (case reports, case series or non-systematic clinical observations). The Expert Panel has confidence that vitamin D supplementation or vitamin D deficiency treatment are, on average, safe and beneficial when used according to the strong recommendations. Weak recommendations necessitate more personalized consideration, and, on average, are safe and beneficial as well.
ReCOMMeNDaTiONS-2018 UPDaTe
General Recommendations 
Recommendations for vitamin D Supplementation in the General Population
Neonates Born at Term and Infants i. 0-6 months: 400 IU/day from first days of life, regardless the way of feeding (1⊕⊕⊕); ii. 6-12 months: 400-600 IU/day, depending on daily amount of vitamin D taken with food (1⊕⊕⊕);
Children (1-10 Years)
i. In healthy children sunbathing with uncovered forearms and legs for at least 15 min between 10.00 and 15.00 h, without sunscreen in the period from May to September, supplementation is not necessary, although still recommended and safe (1⊕⊕⊕); ii. If above insolation guidelines are not fulfilled, supplementation of 600-1000 IU/day is recommended, based on body weight and the dietary vitamin D intake, throughout a year (1⊕⊕⊕);
Adolescents (11) (12) (13) (14) (15) (16) (17) (18) i. In healthy adolescents sunbathing with uncovered forearms and legs for at least 15 min between 10.00 and 15.00 h, without sunscreen in the period from May to September, supplementation is not necessary, although still recommended and safe (1⊕⊕⊕); ii. If above insolation guidelines are not fulfilled, supplementation of 800-2000 IU/day is recommended, based on body weight and the dietary vitamin D intake, throughout a year (1⊕⊕⊕);
Adults i. In healthy adults sunbathing with uncovered forearms and legs for at least 15 min between 10.00 and 15.00 h, without sunscreen in the period from May to September, supplementation is not necessary, although still recommended and safe (1⊕⊕⊕); ii. If above insolation guidelines are not fulfilled, supplementation of 800-2000 IU/day is recommended, based on body weight and the dietary vitamin D intake, throughout a year (1⊕⊕⊕); (12) (13) (14) (15) . Intrinsic and environmental factors such as cloud cover, air pollution, intensive skin pigmentation, advanced age, excessive usage of sun protection cosmetics with sun protection factor above 15, significantly extend the exposure time necessary for achieving sufficient vitamin D supply. The above factors may totally prevent vitamin D skin synthesis even if the appropriate amount of time spent in the sunlight during spring and summer is provided. There are also individuals not adherent to the practice guidelines, or those who fail to follow recommended sensible exposure to sunlight due to specific contraindications. Sun exposure tends to be very limited among children and adolescents because of their indoor extra activities, and also in a large proportion of adult population due to the type of job. In neonates, infants and children younger than 3 years of age, the direct exposure to sunlight without sunscreen is not recommended (http://pediatrics.aappublications.org/ content/pediatrics/early/2011/02/28/peds.2010-3501.full. pdf). Other reasons may include chronic diseases preventing from outdoor activities, cancer phobia or fear of skin aging (6, 14, 15) . 
Seniors (>65-75 Years) and People With a Dark Complexion

Diet
The diet is the alternative source of vitamin D for humans; however in natural conditions, at least in Poland, it is a significantly less effective source, compared to skin synthesis. It is estimated that balanced diet covers up to 20% of the required daily vitamin D intake. Dietary vitamin D is present in two forms. In the food products of animal origin the dominant form of vitamin D is cholecalciferol (vitamin D3), and that of plant and fungal origins-ergocalciferol (vitamin D2). Natural sources of vitamin D mainly comprise fish, such as eel, wild salmon, herring and to a lesser extent-egg yolk, cheese, milk and some mushrooms ( Table 3) . Evaluation of nutritional habits and food composition in different populations showed that, when an additional source such as skin synthesis is scarce, even varied and balanced diet cannot be regarded to match the complete vitamin D requirement. Therefore, an appropriate vitamin D supplementation plays a crucial role in maintenance of the optimal health outcomes (3, 5, 16) .
In terms of prevention of vitamin D deficiency at the population level, a mandatory fortification of selected food products (milk, dairy products, cereals, orange juice, margarine and pasta) is provided in some countries (17) . The extent of fortification varies across different world regions, depending on health policy and governmental strategies. So far, the food fortification has not been customarily applied globally or locally in Poland, resulting in pandemic of vitamin D deficiency according to some reports (1-3). Milk formulas for infants and toddlers are an exception, as these products are enriched with vitamin D in a standard way ( Table 3 ). The amount of 1 l of commercial formula milk is proven to cover the daily vitamin D requirement sufficiently, at least in context of prevention of vitamin D deficiency and nutritional rickets. It should be underlined that the vitamin D supplementation is necessary in breast-fed infants. The vitamin D content in human milk is fluctuating and small (about 40 IU/l), and seems insufficient for a growing child, even if standard recommended intakes of vitamin D are reassured in a breast-feeding mother (18, 19) .
Pharmacological Preparations of Vitamin D
Cholecalciferol (D3) is the most common preparation used as supplementation and treatment of vitamin D deficiency in Poland and Europe, unlike in the USA, where ergocalciferol (D2) is largely used. In Poland, vitamin D3 is available over-the counter at daily doses of 400, 500, 800, 1,000, 2,000 and 4,000 IU. Vitamin D3 is also available as multivitamin preparations, in composite calcium supplements, cod liver oil and, less frequently, in some food products fortified with vitamin D. The administration of vitamin D as a combination containing calcium or vitamin K2 (MK7) or in conjunction is not recommended presently. Efficacy of simultaneous intake of the vitamins K2 and D, as a factor preventing calcification of vessels and soft tissues, as well as enhancing bone mineralization, has not been proven. Vitamin D should not be administered together with high-fiber cereals (oatmeal and bran), resins binding steroids (colestyramine), laxatives or stool softeners.
Calcifediol, 25(OH)D3, is an essential preparation improving vitamin D supply, however, this medication is used mainly in patients with impaired hepatic metabolism of vitamin D, coincident chronic liver diseases, cholestasis, long-term therapy with glucocorticosteroids and anticonvulsants (9) .
Active metabolites and analogs of vitamin D, such as alfacalcidol (1αOHD3), calcitriol [1α,25(OH)2D3] and paricalcitol [19nor1α25(OH)2D2] should not be considered as an alternative way of vitamin D supplementation, and in consequence, monitoring of the therapy based on active metabolites and analogs, using serial prospective evaluation of 25(OH)D concentration demonstrates a limited value. Alfacalcidol is most often used in cases presenting with impaired renal metabolism of vitamin D and in diseases with a decreased activity of 1α-hydroxylase, such as renal failure, nephrotic syndrome, chronic kidney disease, hypophosphatemic rickets and other vitamin D-resistant rickets, as well as in hypoparathyroidism. Calcitriol has been assigned similar application; however, it is used less frequently and is less available in Poland. Paricalcitol is a newly developed vitamin D analog, used for prevention and treatment of secondary hyperparathyroidism resulting from chronic renal failure (20) (21) (22) . It should be underlined again, that the use of analogs and active metabolites of vitamin D does not lead to expected changes of 25(OH)D concentrations and is not an alternative mode for supplementation with the use of vitamin D (or with calcifediol in specific cases). The use of analogs does not detract the patient from necessity to a concurrent vitamin D intake, just in the context of pleiotropic health benefits.
vitamin D Metabolism
Cholecalciferol-produced in the skin, and cholecalciferol (and ergocalciferol)-absorbed in the small intestine (from diet and pharmacological supplements), are transported to the liver and bound to the DBP. In the liver, the first stage of biosynthesis of an active vitamin D is activated. After enzymatic hydroxylation at the carbon-25, 25-hydroxyvitamin D-25(OH)D is formed. This reaction is catalyzed by 25-hydroxylase, which compromises a group of hydroxylases, being part of cytochrome P450 (CYP27A1, CYP3A4 and CYP2R1) (23, 24) . The concentration of (25) or excessive synthesis of 1,25(OH)2D directly resulting from mutation of SLC34A1 gene coding sodium-phosphate co-transporter (NaPi-IIA) in the kidney (26) . In both cases, the risk of hypervitaminosis D is increased even if prophylactic doses of vitamin D are used.
Calcemic effects of vitamin D
Classic and well recognized action of vitamin D consists of its key role, besides PTH and calcitonin, in regulation of calcium and phosphorus homeostasis. The main effector organs involved in the regulation of calcium and phosphorus homeostasis by vitamin D action include intestine, bones and kidney. In the intestine, under the influence of 1,25(OH)2D, synthesis of a protein binding calcium and calcium absorption are increased, in bones-calcium and phosphates (in case of hypocalcemia) are released, and in kidneys-calcium is reabsorbed with input from PTH activity. The main procalcemic action of calcitriol is the inhibition of PTH secretion in the feedback via calcitriol, resulting in the increase of calcium and phosphates concentrations in serum (27) .
Vitamin D action on bone metabolism is mediated by the receptor activator of nuclear factor NF-κB (RANK)/RANK ligand (RANKL) system, responsible for osteoclastogenesis. Calcitriol increases RANKL expression in osteoblasts, which in turn activates RANK receptors in osteoclast precursors leading to formation of mature osteoclasts. The resorption action of osteoclasts releases calcium and phosphates from the skeletal system into circulation (28) .
Vitamin D, due to its action regulating calcium-phosphorus metabolism, plays a significant role mainly in tissues and organs rich in these minerals, i.e., the skeletal system and teeth. Vitamin D deficiency in children is a classic risk factor for nutritional rickets, a disease presenting with bone deformations of varying severity as well as impaired mineralization and decreased bone mass. In adults and adolescents, after growth plate fusion, vitamin D deficiency may lead to osteomalacia and osteoporosis. In all age groups, a severe vitamin D deficiency is related to bone pain of various intensity and localization (predominantly in the lower limbs and feet) as well as increased susceptibility to bone fractures. Advanced stages of nutritional rickets and osteomalacia may be even the life-threatening conditions, characterized not only by bone deformations, but also by hypocalcemic seizures (29, 30) , tetany (31, 32) , severe bone pain and significant muscle weakness (33, 34) , hypocalcemic cardiomiopathy, even resulting in circulatory failure (35-38), and by disorders of psychomotor and physical development (39), including short stature (4, 40) .
In the scenario of vitamin D deficiency, a three-stage regulatory mechanism was described. Initially, a compensatory increase of PTH secretion to sustain normocalcemia is observed. However, PTH reveals an ability to auto-regulate, and a relative resistance to PTH may develop resulting in decreased calcium concentrations and increased phosphate concentrations (similarly to a PTH resistance in pseudohypoparathyroidism). At this stage, typical symptoms of hypocalcemia, including tetanic convulsions, may occur. Osteopenia is visible on radiographs, without typical rickets lesions. In the next stage, when the severity of vitamin D deficiency continues to progress and PTH secretion is further stimulated, a PTH resistance gets overcome leading to improved calcemia but also to hypophosphatemia and clinical and radiological manifestation of rickets. ALPL increases then, whereas concentration of 1,25(OH)2D is normal or increased. At the final stage, the vitamin D deficiency becomes very severe and 1,25(OH)2D synthesis is markedly inhibited, the calcitriol concentration decreases, and subsequently absorption of both calcium and phosphorus is impaired, along with persistent elevation of PTH and increased ALPL (18).
The mechanism described above highlights that results of biochemical assays may reveal varied values, depending on the severity of vitamin D deficiency. Therefore, isolated assays of 1,25(OH)2D concentrations may be misleading. In moderate vitamin D deficiency, as well as in the course of treatment, concentration of calcitriol may be normal or high, whereas in overdosage of vitamin D it may be normal or decreased (41, 42) . These alternations prove a limited clinical utility of 1,25(OH)2D assays, as this metabolite shows low stability and is a subject to multifactorial influences, including hormonal regulation.
Pleiotropic action of vitamin D
Development of molecular studies and discovery of VDR in many tissues, which do not take part in calcium-phosphorus metabolism, have initiated an era of intensive research on other non-classic, extra-skeletal functions of vitamin D (43) (44) (45) (46) . The activity of vitamin D in effector tissues is exerted through its genomic and non-genomic action. An active form of vitamin D in a number of tissues and cells binds with VDR in the cell nucleus and then it forms a heterodimer with 9-cis retinoic acid receptor (RXR), which shows property of a transcription factor, so the genomic action is initiated. It is estimated that in this way calcitriol takes part in regulation of several hundred genes in the human genome (47, 48) . Non-genomic effects are mediated by a receptor localized in a cellular membrane, which is different from the nuclear receptor, and it triggers intracellular metabolic pathways, modulating effects resulting from the gene expression (49, 50) . The non-genomic, rapid responses related to calcitriol apply to the regulation of ion channels, phosphatases, phospholipases, kinases and signaling factors that may independently regulate gene expression and its products (49) (50) (51) (52) .
It has been reported that calcitriol takes part in numerous physiological processes, including enhancement of proliferation and differentiation of immune cells (52, 53) . It induces apoptosis of neoplastic cells and inhibits their multiplication (52, 53) , increases production of cathelicidin and beta-defensin (51, (54) (55) (56) , modulates lymphocyte activity (51), Th1 and Th2 lymphocyte ratio (51, 57) , decreases concentrations of proinflammatory cytokines (IL-1, TNFα), simultaneously increasing anti-inflammatory cytokines (IL-4, IL-5 and IL-10) (51, 58), decreases renin secretion and in this way reduces activity of the renin-angiotensinaldosteron system (59, 60) , inhibits angiogenesis (61) (62) (63) , and has favorable effect on calcification processes in blood vessels (64) (65) (66) (67) , stimulates synthesis of neurotrophic factors (68, 69) and inhibits fibrosis in kidneys (70, 71) . Vitamin D deficiency decreases insulin secretion (72) . Vitamin D also shows strong immunomodulating action (58, 73) . High content of VDR in cells of the immunocompetent system, particularly in macrophages, dendritic cells and lymphocytes T and B supports the concept of the essential role of vitamin D in anti-infectious immunity, in the course of acute and chronic inflammatory processes as well as in autoimmune diseases (45, 46, 58, 73) .
The pleiotropic aspect of vitamin D action was tested in numerous observational studies, suggesting association between low serum concentration of 25(OH)D and increased risk of neoplasms (among others cancers of the colon, breast, ovary, prostate, pancreas, skin, kidneys, brain tumors, multiple myeloma and leukemia) (74) (75) (76) (77) (78) , immunological diseases [multiple sclerosis (79) (80) (81) (82) , asthma (83, 84) , non-specific inflammatory bowel diseases (85, 86) and systemic lupus erythematosus (87, 88) ], autoimmune endocrine disorders [diabetes type 1 (89, 90) (109, 110, 114) ]. Vitamin D deficiency is also associated with increased mortality in the general population (115) (116) (117) , in patients in intensive care units (118) (119) (120) , and in patients with neoplasms (121) . A better vitamin D supply, reflected by an optimal 25(OH)D concentration, may alleviate invasiveness of a neoplastic process and micrometastases, as well as improve disease prognosis, and also limit risk of recurrence (122) . Largely conducted RCT studies, however, have not shown consistent results, likely due to a short time of follow-up, type of regimen and different levels of a supplementary dose (123, 124) . Nevertheless, many of these studies showed health benefits related to vitamin D supplementation. Presently, however, it cannot be stated explicitly that vitamin D deficiency is a direct cause of many disorders and their sequelae, and the hypothesis of reverse causality gains significance in the light of systematic reviews of meta-analyses and RCTs (125, 126) . Taking into account on-going studies presenting potential health benefits and negligible health risk resulting from supplementation and maintenance of optimal and safe 25(OH)D concentrations, it is indicated to recommend prophylactic administration of vitamin D in the general population, when skin synthesis is insufficient for different reasons.
vitamin D Safety
Serum concentration of 25(OH)D up to 100 ng/ml is regarded safe in the general population of children and adults, although in preterm neonates, being a specific group, an increased risk of hypercalcemia has been reported at the 25(OH)D values >80 ng/ ml (127) . No evidence exists until now that these values may be exceeded when appropriate doses of vitamin D are used. In fact, symptoms of vitamin D toxicity are observed very rarely. They are connected with hypercalcemia and hypercalciuria and may occur when vitamin D intake is uncontrolled and excessive, resulting in concentrations of 25(OH)D above 150-200 ng/ml (42, 128) . Exceptional conditions comprise individuals with vitamin D hypersensitivity, and also with idiopathic infantile hypercalcemia (IIH) (24, 26) , Williams-Beuren syndrome (129), granulomatous diseases (130) and some lymphomas. Vitamin D hypersensitivity may result from impaired catabolism of calcidiol and calcitriol or an excessive, uncontrolled by the feedback, synthesis of calcitriol (local or systemic) (24) . The relationship between CYP24A1 gene mutation and autosomal recessive IIH has been proven (25) . It was also shown that subsequently discovered mutations of CYP24A1 caused loss of function of 24-hydroxylase and clinically manifested as late as in adulthood (131, 132) . Hypervitaminosis D may also result from an excessive synthesis of 1,25(OH)2D in the case of mutation of SLC34A1 gene, coding renal sodiumphosphate co-transporter (NaPi-IIA) (26) . It is known that in an endocrine (renal) pathway, processes of calcitriol synthesis involving CYP27B1, and its degradation involving CYP24A1, are also regulated by FGF-23. Disorders of phosphorus homeostasis as a result of SLC34A1 mutation lead to the decrease in FGF-23 activity; FGF-23 in physiological conditions limits activity of 1α-hydroxylase (CYP27B1) and stimulates 24-hydroxylase activity (CYP24A1). A decreased activity of FGF-23 due to SLC34A1 mutation and subsequent hyperphosphaturia and hypophosphatemia, indirectly stimulate synthesis of 1,25(OH)2D that may produce hypercalcemia, hypercalciuria and nephrocalcinosis (133) . In case of the diagnosed vitamin D hypersensitivity while supplementing vitamin D deficiency, it is suggested to maintain 25(OH)D concentrations within lower ranges, i.e., 20-25 ng/ml rather than within ranges regarded as optimal, i.e., 30-50 ng/ml (134) . It should be emphasized that at the general population level, vitamin D supplementation with use of daily doses that are recommended for a given age and body mass is safe and reasonable, whereas the incidence of vitamin D hypersensitivity seems to be low or at least it should be precisely investigated. Additionally, upper tolerable limits (UL) have been determined for the general healthy population in order to limit uncontrolled use of vitamin D. Upper tolerable limits should not be confused with recommended doses during well-controlled treatment of vitamin D deficiency. UL are considered safe for the healthy population and are commonly accepted worldwide by international scientific societies [e.g., Institutes of Medicine (IOM, USA) (135), The Endocrine Society (USA) (136) and European Food Safety Authority (European Union) (137)]. In the general population at the neonatal and infantile periods, the UL value equals to 1,000 U/l, in the period of 1-10 years of age-2,000 IU, and from 11 to 18 years of age and in adults-4,000 IU, respectively.
In cases of fully symptomatic vitamin D intoxication, resulting from overdose, the general therapeutic management includes hydration with normal saline followed by loop diuretics and the use of glucocorticoids, bisphosphonates, calcitonin or ketoconazole is often considered as the second-line treatment. Effective therapy is provided also by the anticonvulsant use. Anticonvulsants/ antiepileptic drugs are known as potent inductors of cytochrome P450 activity and particularly its isoform CYP3A4. Induction of this enzyme localized in the liver and intestines, contributes to an increase of metabolic clearance of essential vitamin D metabolites, such as 25(OH)D and 1,25(OH)2D (138) . Polar products of vitamin D, formed in extra hydroxylation pathways, are then quickly excreted from the body (138, 139) . When vitamin D status is normal, abovementioned processes result in vitamin D deficiency and mineral disturbances (138) (139) (140) . Based on the above phenomenon, there have been two successful published attempts of removal of vitamin D excess in neonates (7 and 1.5 months old), casualties of its erroneous overdose (128, 141) . In both cases, apart from other modes of treatment, anticonvulsants were administered (phenytoin 5 mg/kg/day for 17 days, phenobarbital 5 mg/kg/day for 133 days in the first case, and phenobarbital 3 mg/kg/day for 4 months in the other case). In both cases, at the end of treatment period, a decrease of 25(OH) D concentrations from approximately 400 to 40 ng/ml and from 160 ng/ml to normal ranges, respectively, was found. An attempt to withdraw phenobarbital (after 44 for 14 days) caused recurrence of intoxication symptoms (128) . Eventually, in both cases monitored parameters of mineral metabolism returned to normal values.
Terminology
The Panel proposed to systematize the terms and nomenclature used in everyday medical practice in Poland. According to panelists' opinion, it is not justified to use the term "hypovitaminosis D" solely on the basis of 25 
Review OF ReCOMMeNDaTiONS
In available literature, the most commonly quoted and discussed position papers are the guidelines elaborated by IOM in 2010 (135) , and the practice guidelines issued by the Endocrine Society in 2011 (136) .
Based on the evidence available at the time, the IOM focused on calcium and phosphorus metabolism, including benefits limited to bone tissue. As a result, the target for vitamin D supplementation in the general population, recognized by the IOM, was to obtain 25(OH)D concentration of >20 ng/ml (135) . In response to the IOM proposals, the recommendations of the Endocrine Society included general healthy population and populations with chronic conditions; furthermore, both the classic and pleiotropic action of vitamin D were incorporated in the integrated guideline. The Endocrine Society's minimal target value of 25(OH)D concentration was set on 30 ng/ml, and the values of <30 and <20 ng/ml were labeled as insufficient or deficient, respectively (136) . Guidelines concerning the optimal 25(OH)D concentrations and vitamin D supplementation vary across European countries: Scandinavian countries (Denmark, Finland, Iceland, Norway and Sweden) established the target 25(OH)D concentration of ≥20 ng/ml (142) , and a similar threshold concept was accepted in Germany, Austria and Switzerland (3).
The recommendations prepared for Central Europe were the closest to the position statement of the Endocrine Society (9) . The background in establishing those guidelines were documents by the European Food Safety Authority, published in 2012, and the global discussion of the scientific body over validity and adaptation of the proposals by the IOM and the Endocrine Society. The Guidelines for Central Europe set down the 25(OH)D concentrations of 30-50 ng/ml as optimal in relation to all potential health benefits (9) .
Assuming that the aim of vitamin D supplementation is to achieve and to maintain the optimal concentrations of 25(OH) D, as a substrate for renal and extrarenal 1α-hydroxylation (CYP27B1), and in consequence-synthesis of calcitriol, recommendations including endocrine, paracrine and autocrine effects of 1,25(OH)2D seem to reflect a holistic view on vitamin D deficiency and human health. The maintenance of recommended optimal 25(OH)D concentrations (>30-50 ng/ml) is reinforced by results of numerous cross-sectional and epidemiological studies, as well as several prospective trials, showing safety of such concentrations, not causing hypercalcemia or hypercalciuria. Another argument supporting 25(OH)D concentration of >30-50 ng/ml as the optimal, involves kinetics of 25-hydroxylase that showed 50% of its activity at the concentration of 40 ng/ml (143, 144) . An important evidence was also reported by Priemel et al., who performed histomorphometric analysis of iliac crest bone biopsies in 675 subjects and revealed the osteomalacia lesions in 26% individuals, including 21% of the examined with 25(OH)D concentrations within a range of 21-29 ng/ml (145) . Furthermore, osteomalacia signs were not observed in investigated bone biopsies of cases with 25(OH)D concentrations of >30 ng/ml (145) . Moreover, studies carried out in pregnant women showed convincing evidence of health benefits for both woman and child that were associated with vitamin D supplementation and with achieved and maintained 25(OH)D concentrations close to 40 ng/ml (146) (147) (148) .
Global guidelines published in 2016 considered 25(OH)D concentrations of >20 ng/ml as optimal (8) . The supplementation regimen in almost all age groups included significantly lower vitamin D doses as compared to those recommended by the Endocrine Society (136) and for Central Europe (9) . As a result, also in Poland, practitioners were forced to choose between the global and local recommendations. It should be emphasized, however, that global recommendations consider supplementation only in the context of prevention and treatment of nutritional rickets, and do not refer to other, widely evidenced health benefits related to vitamin D action, as it was pointed out by the authors of that document (8) . Interestingly, the vitamin D doses recommended in the global consensus for the management of vitamin D deficiency confirmed by laboratory assays are very similar to the Central European recommendations. In neonates they are even higher (Central European recommendations-1,000 IU/day and global recommendations-2,000 IU/day; Table 4 ). The global recommendation of using a single loading dose of vitamin D (from 50,000 to 300,000 IU at a time) in treating deficiency in subjects older than 3 months of age, is disputable. A question arises whether it is a return to a historic recommendation of therapy based on a single mega-dose? Absolutely it is not. Loading doses should be justified only in particular situations, when everyday regular supplementation of vitamin D is not possible because of socioeconomic reasons or limitations of the health care system and infrastructure facilitating distribution of vitamin D supplements. In case of loading doses, the risk of hypercalcemia should be carefully taken into account, as it was elsewhere found in 6.5% of children treated with single high doses of vitamin D (8) .
In the global consensus, additional attention is paid to relatively low recommended dietary calcium intake, considered as sufficient in preventing nutritional rickets. In children, the following daily calcium intake was recommended: up to 6 months of age-200 mg, 6-12 months-260 mg and after 12 months of age-500 mg. The recommendations for Central Europe (2013) did not arise an issue of calcium intake, however, this was included in Polish recommendations published in 2009 (10) . The doses recommended then were definitely higher, particularly in older age groups and increased with age, in the range from 500 to 1,300 mg/day ( Table 4 ). The American Institute of Medicine enforces similar recommendations, including calcium intake of 700-1,300 mg/day for the population aged 1-18 years, depending on a child's age (135) .
DiSCUSSiON
Recommendations concerning vitamin D supplementation have been changing over the years and have followed the most recent scientific developments and clinical observations. However, even current doses recommended by scientific societies differ from each other significantly and vary from 200 to 2,000 IU/day (149). This results mainly from discrepancies concerning minimal target 25(OH)D concentration, which was defined by ranges between 10 and 40 ng/ml, depending on how different expert groups perceived vitamin D action (135) (136) (137) . Most endocrine societies, including the Endocrine Society (USA), and also some dealing with bone health, such as the International Osteoporosis Foundation, reckon the 25(OH)D concentration above 30 ng/ ml as that required to achieve health benefits. This value was also determined as a lower range of the optimal 25(OH)D concentration in 2013 Central European recommendations and is now maintained in the present recommendations for Poland (9, (134) (135) (136) (137) 150) .
The Expert Panel decided on an update of the recommended daily doses for the general population and for the groups at the increased risk of vitamin D deficiency that have been in operation in Poland since 2013. The Panel has decided to add additional target groups for vitamin D supplementation, including adolescents aged 11-18 years, older seniors aged >75 years, and also to modify previous Central European guidelines for the preterm babies.
Indisputably, individuals aged 11-18 years are among the groups of increased risk of vitamin D deficiency, however due 
Recommendations for Poland 2009
Recommendations for Central europe 2013
Global recommendations 2016
Definition of vitamin D supply based on 25(OH)D concentration in the serum (1 ng/ml = 2.5 nmol/l)
Optimal concentration (sufficiency) Children and adolescents: 20-60 ng/ml Adults and seniors: 30-80 ng/ml >30-50 ng/ml >20 ng/ml Suboptimal concentration (insufficiency) Not defined >20-30 ng/ml 12-20 ng/ml Deficiency <10 ng/ml 0-20 ng/ml <12 ng/ml Toxic concentration (toxicity) Not defined >100 ng/ml >100 ng/ml
Recommended doses of vitamin D-supplementation (40 iU = 1 µg) 0-6 months 400 IU/day 400 IU/day 400 IU/day 6-12 months 400 IU/day 400-600 IU/day 400 IU/day 2-18 years 400 IU/day 600-1,000 IU/day 600 IU/day >18 years 800-1,000 IU/day 800-2,000 IU/day 600 IU/day Pregnancy and lactation 800-1,000 IU/day 1,500-2,000 IU/day 600 IU/day
Recommended doses of vitamin D-treatment of the deficiency (40 iU = 1 µg)
<1 month 1,000 IU/day 1,000 IU/day -<3 months --2,000 IU/day 1-12 months 1,000-3,000 IU/day 1,000-3,000 IU/day -3-12 months --2,000 IU/day 2-19 years up to 5,000 IU/day 3,000-5,000 IU/day -2-12 years --3,000-6,000 IU/day >19 years up to 7,000 IU/day 7,000-10,000 IU/day ->12 years --6,000 IU/day
Single loading doses of vitamin D for the management of the deficiency (40 iU = 1 µg) to rapid and significant weight gain, an acceleration of skeletal growth, rapid bone turnover and modeling, redistribution of muscle-fat compartments and the other biological and behavioral aspects of pubertal transition, a too low supply of vitamin D during adolescence is of concern. Further, during these critical time frames of development, the risk of vitamin D deficiency and related adverse health outcomes may be exacerbated by sedentary behavior and time spent indoor, dietary habits and even use of restrictive diets. These numerous risk factors for vitamin D deficiency taken together pointed to this group as a target group of special concern and highlighted a need to increase a recommended vitamin D daily dose range to 800-2,000 IU, depending on body weight and season of the year. The British RCT study comprising a group of 110 children and adolescents with normal body weight, aged 14-18 years, evaluated efficacy of vitamin D supplementation at doses of 0, 400 and 800 IU/day, applied in the period between October and March (20 weeks), in order to determine distribution of nutritional requirements to maintain 25(OH)D concentrations ranging from >10 and >20 ng/ml. Data analysis showed that in the examined group of Caucasian children the maintenance of 25(OH)D concentration >10 and >20 ng/ml (in 97.5% of the examined) required a vitamin D supplementation at doses of 400 and 1,200 IU/day, respectively. Interestingly, none of the participants reached the 25(OH)D concentration of 40 ng/ml (151) . The RCT of 96 children and adolescents, aged 8-14 years, carried out in the USA (Pittsburg) found that maintenance of 25(OH)D concentrations >20 ng/ ml in the period from October to April in 90% of the examined group required vitamin D supplementation at a dose of 1,543 IU/ day, whereas an estimated dose of 2,098 IU/day appeared necessary to provide maintenance of this concentration in 97.5% of studied individuals (152) . In another RCT, comparing efficacy of vitamin D supplementation applied for 6 months at doses of 600, 1,000 and 2,000 IU/day in the group of 685 school-aged children, the best effects of the supplementation, as expressed by 25(OH)D concentrations of ≥30 ng/ml, were revealed in the 2,000 IU/day group. In this group 25(OH)D concentration of ≥30 ng/ml was obtained in 60% of children already after the 3 months of trial and the use of 2,000 IU/day resulted in the mean 25(OH)D concentration of 33.1 ng/ml (153) . The recent study of 1007 Polish children (6) , hospitalized due to symptoms of skeletal disorders, revealed that vitamin D deficiency, including a severe vitamin D deficiency (<10 ng/ml), was noted more frequently at the pubertal period and at adolescence as compared to childhood and the prepubertal children, despite the availability of national guidelines.
In the eldest seniors, aged >75 years, according to the Panel opinion, vitamin D should be supplemented throughout the year at doses of 2,000-4,000 IU/day, depending on body weight. The recommended dosing range for the eldest seniors up to 4,000 IU/ day was considered by panelists as effective enough to achieve the target 25(OH)D concentration of >30-50 ng/ml in at least 90% of the elderly in Poland. The group of the eldest seniors is another target group at increased risk of vitamin D deficiency, as well as falls and fragility fractures. Available RCT studies and meta-analyses evidenced that 25(OH)D concentrations ranging >24-50 ng/ml, as a result of vitamin D supplementation of seniors and the eldest seniors, were associated with a significant decrease of risk of falls (by 19%) (154), a significant decrease of risk of proximal femoral fractures (by 37%) (155) and significantly decreased risk of other fractures (by 31%), compared to controls. Although most studies reviewed recommended supplemental doses >800 IU/day, still about half of the seniors and the eldest seniors supplemented with vitamin D did not reach 25(OH)D concentrations considered as optimal. Therefore, after numerous discussions, the Expert Panel recommended a full eradication of vitamin D deficiency, using doses 2,000-4,000 IU/day in order to achieve and maintain the optimal 25(OH)D concentration and also to provide the eldest seniors with potential benefits resulting from pleiotropic vitamin D action. The above recommendation is well-matched to the American Geriatric Society guidelines (156) .
The Expert Panel, basing on the review of the literature and RCT studies, has decided to modify the Central European recommendations for preterm babies. RCT studies published during the last 5 years revealed advantages of vitamin D supplementation at doses of 800-1,000 IU/day in neonates born at ≤32 weeks of gestation and in neonates born with very low birth weight (<1,500 g) (157) (158) (159) . In the study comparing effects of vitamin D supplementation (1,000 vs 800 vs 400 IU/day), the percentage of the preterms with vitamin D deficiency at 36 weeks of the postmenstrual age was 2.5, 9.8 and 22.5%, respectively (159) . In a group of more preterm babies (born at ≤28 weeks of gestation), after 4 weeks of vitamin D supplementation (800 vs 200 IU/day vs placebo), the percentage of the preterms with vitamin D deficiency was 0, 16 and 41%, respectively (158) . In the subgroup supplemented with vitamin D dose of 800 IU/day, the majority of investigated cases reached 25(OH)D concentrations >60 ng/ml, despite that as high as 67% preterms presented vitamin D deficiency at birth. An observational study of 66 preterm neonates (mean birth weight 970 g, 27 weeks of gestation) showed that vitamin D supplementation at a dose of 800 IU/day was effective to reduce prevalence of severe vitamin D deficiency, evaluated at 36 weeks of the postmenstrual age, from 41 to 0%, as well as to improve prevalence rate of 25(OH)D concentrations >30 ng/ml from 10 to 72% (160) . Unfortunately, the problem of vitamin D deficiency in the preterm neonates is also common in Poland (161) . The risk of vitamin D deficiency at birth rises along with the shortening of pregnancy duration and the risk of preterm delivery increases with severity of vitamin D deficiency in pregnant women (146) (147) (148) . The updated vitamin D supplementation doses seem effective for the quick improvement of vitamin D status of preterm neonates, however, after a one month of vitamin D supplementation, according to panelists guidelines for preterms, it is recommended to evaluate 25(OH) D concentration and if necessary modify the dosage. Because of the concern about adverse effects and risk of overdosing, studies with lower vitamin D doses (200 IU/day) were also conducted in the preterms born at ≤32 weeks of gestation. At the 36 week of the postmenstrual age, vitamin D supplementation at a dose of 200 IU/day appeared not fully effective and vitamin D deficiency was noted in up to 40% of cases born at <28 weeks of gestation and 30% of cases born at 28-32 weeks of gestation (162) . It seems that in more mature preterm neonates (with relatively lower risk of the severe vitamin D deficiency), vitamin D supplementation at a dose of 400 IU/day, that is also recommended for in-term born neonates, should provide adequate vitamin D supply (163) .
The Expert Panel is of the opinion that population-based 25(OH)D concentration screening is not justified, however recognizes strong indications for 25(OH)D concentration assessment in an increasing number of clinical conditions in order to optimize the course and to minimize complications of the underlying disease ( Table 1) . The Panel shares the position statements of the Endocrine Society that the vitamin D supplementation in groups at risk of vitamin D deficiency that need special concern, including women planning pregnancy, pregnant and lactating women and the preterm babies (<32 weeks gestation) should be provided and followed under the control of 25(OH)D concentration and its changes (136) . Some available reports pointed on vitamin D supplementation doses of 4,000-6,400 IU/day as safe, effective and beneficial for pregnant and lactating women as well as for offspring (146) (147) (148) . In contrast, studies performed in Poland and Canada (Calgary, 51°N) evidenced a low effectiveness of vitamin D supplementation at doses 600-800 IU/day for beneficial pregnancy outcomes (16, 164) . Considering the safety of vitamin D supplementation during pregnancy (to a lesser extent during lactation) and a high probability of use of multicomponent preparations that usually contain 200 IU vitamin D per serving, the Expert Panel recommends the dose of 2,000 IU/day for the general population of pregnant and lactating women with unknown 25(OH)D concentration. Some pregnant women may require higher doses of vitamin D to achieve optimal 25(OH)D concentration, however, vitamin D supplementation using doses higher than 2,000 IU/day should be carried out based on initial In the context of therapeutic dosing of vitamin D, the Expert Panel is of the opinion that single loading doses of vitamin D provided at the 3-month intervals should not be recommended in Poland. An approach for the loading doses use was proposed in the 2016, by global consensus focused on prevention and therapy of nutritional rickets, as an alternative therapeutic procedure for patients suffering from nutritional rickets, exclusively if the regular daily vitamin D supplementation is not possible for various reasons (8) . Taking into account a higher risk of hypercalcemia as a result of loading doses (8) and previous Polish and European experience with loading doses (42) , as well as a relatively easy, permanent access to vitamin D supplements and health care in Poland, an implementation of very high doses would not be justified.
Recently, a regimen of a single dose of 30,000 IU of vitamin D3 available on prescription, has been promoted in Poland, with an indication for administration once a month in adults, the elderly and adolescents older than 12 years of age. The standpoint of the Expert Panel is that vitamin D intake at a dose of 30,000 IU, regardless the regimen [once a month according to summary of product characteristics (SPC) or more often according to some positions (167) ], is considered neither as appropriate nor as safe management, if a prior assessment of 25(OH)D concentration and the risk factors for vitamin D hypersensitivity were not investigated. In the aspect of prevention of vitamin D deficiency in the general population (considered as healthy) or even in the groups of risk of deficiency, vitamin D supplementation at a cumulative dose equivalent to 15 or 30 daily doses (2,000 or 1,000 IU/day, respectively) rises concerns about safety. In the most extreme regimen of supplementation with use of cumulative dose recently promoted in Poland (30,000 IU), for example in older obese adolescents and obese adults, the recommendation of doses constituting two to three times the dose recommended for peers with normal body weight (i.e., 60,000-90,000 IU, respectively) even twice a month according to some reports (167), should be considered unwarranted and very risky. Panel is of the opinion that vitamin D supplementation at a single dose of 30,000 IU, diverging from the SPC (once a month) may be unfavorable even as an adjunct to osteoporosis treatment. In a RCT of 200 subjects aged >75 years an increased risk of falls as a result of use of 24,000 IU with 300 µg of calcifediol once a month, as well as an increased risk of falls as a result of 60,000 IU once a month were both evidenced (168) .
The Expert Panel in the updated Polish recommendations as well as others [the previous Endocrine Society (136) and Central European (9) guidelines] do acknowledge abnormal body weight as a significant variable affecting vitamin D status and recommend obese persons from general population a doubled daily dose of vitamin D. A weak but significant negative correlations were shown between 25(OH)D concentrations and body weight as well as BMI (kg/m 2 ) in Poland (7). However, vitamin D deficiency is more often noted in obese persons, irrespective of age (169) . Our guidelines recommend a two times higher daily dose for obese persons in relation to normal body weight counterparts. Further, age-and body weight related ranges of vitamin D for daily dosing, proposed by experts for use in general population, most likely will help to deal also with underweight cases. Our approach is consistent with the Endocrine Society's recommendations (136) and is supported by results of large surveys that estimated two to three times higher vitamin D daily dose for obese subjects, 1.5 times for overweight, and pointed that underweight persons may need lower vitamin D doses to achieve target 25(OH)D concentration when compared to individuals with normal body weight (170) (171) (172) .
The Expert Panel recommends that vitamin D supplementation in individuals with an assayed 25(OH)D concentration should be based on the vitamin D status diagnosed according to recommended concentration ranges and should consider previous prophylactic management. Above statement relates to common observation that guidelines for vitamin D supplementation are not implemented or are not carried out properly and the fundamental problem is non-compliance (5, 6). In individuals declaring supplementary vitamin D intake with revealed abnormal 25(OH)D concentration value (low, high, too high, too low, etc.) the first line of management should be based on evaluation of regularity of vitamin D use, the dosage, a choice of preparation and the way of administration (with or without fatcontaining products-depending on the preparation). A simple correction of management of vitamin D deficiency usually is sufficient enough. However, if the vitamin D supplementation was compliant to recommended but a response was not satisfying, expressed as 25(OH)D concentration still below optimal value range, it is recommended to increase a daily dose by 50-100% or to introduce therapeutic doses-depending on a severity of vitamin D deficiency. If vitamin D supplementation was not so far implemented, it should be started immediately, including the use of therapeutic doses in individuals showing severe deficiency (25(OH)D <10 ng/ml) (Figure 1) . The 25(OH)D follow-up and the range of additional investigations should depend on a severity of vitamin D deficiency. The Expert Panel emphasizes significance of appropriate dietary calcium intake during the course of vitamin D supplementation and treatment of vitamin D deficiency. If dietary sources are considered as not effective, additional pharmacological supplementation with calcium salts preparations is recommended, preferably in a few divided daily doses due to higher absorption rate and the lower risk of periodic hypercalciuria. At the current state of knowledge, it is recommended to maintain existing calcium intake guidelines for Polish population, depending on the age (10).
SUMMaRY
Vitamin D deficiency is an important public health problem in Poland that without appropriate preventive actions may escalate as a result of the on-going changes of life style, unfavorable nutritional habits as well as limited vitamin D supply from natural sources (both dietary and UVB) (4-7). It is necessary to introduce and pursue recommendations in its updated form concerning recent perspective on the prevention and treatment of vitamin D deficiency in all age groups. The synopsis of the guidelines is shown in Figure 1 . This task should be a priority for doctors of all specialties, primarily for general practitioners, as well as people shaping health policies in Poland. It is essential particularly in the context of present knowledge, which provides evidence not only of calcemic action of vitamin D, but also of its pleiotropic effects. The list of classic and non-classic-pleiotropic action of vitamin D and associated health benefits becomes longer and longer. The optimal 25(OH)D concentrations for different endocrine, autocrine and paracrine pathways are indicated as an essential factor in preventing osteoporosis and falls, rickets and osteomalacia, as well as autoimmune diseases, including multiple sclerosis, diabetes type 1, systemic lupus erythematosus, infectious diseases, including tuberculosis and influenza, cardiovascular diseases, neurocognitive disorders, including Alzheimer disease, autism, pregnancy complications, diabetes type 2, as well as decrease of incidence rate and improvement of survival rate and quality of life in malignancy and overall mortality. Despite discussions on causality between vitamin D deficiency and a given disease or a risk of its development, and also in a view of the magnitude of the problem of vitamin D deficiency in the general population and in patients, the Expert Panel recommends implementation of updated guidelines dedicated to prevention and treatment of vitamin D deficiency to a routine everyday practice of physicians and clinical dieticians. 
